Aurobindo Pharma (4QFY24): Strong Q4, Eugia’s USFDA Issues Key Concern. Maintain ADD
EBITDA (+68% YoY) was led by 17% sales growth (-4% QoQ US but up 18% YoY, +10% EU, and +49% YoY in growth markets), higher gross margin (+490 bps YoY)
247 Views
Aurobindo Pharma (4QFY24): Strong Q4, Eugia’s USFDA Issues Key Concern.
ARBP expects to maintain US oral solid business growth momentum, led by new launches and volume gain in the base business
239 Views
Pick of the Week - Aurobindo Pharma Ltd - 04 MAR 2024
The company is engaged in the development, manufacturing, and commercialization of a wide range of generic pharmaceuticals, branded specialty...
279 Views
Aurobindo Pharma Ltd - Several Growth Levers in Place to Drive Topline
Aurobindo Pharma's PAT stood above our estimates by 14%. The company’s consolidated revenue grew by 25.8% YoY and gross margins improved by 122bps...
248 Views
Aurobindo Pharma Ltd - Number of Growth Levers in Place to Drive Topline
Aurobindo Pharma's PAT stood above our estimates by 3.7%. The company’s consolidated revenue grew by 9.9% YoY and gross margins improved by 24bps YoY.
391 Views